Interaction of Semaglutide and Ziprasidone in a Patient With Schizophrenia: A Case Report.

Hejdak D, Razzak AN, Sun L, Rahman M, Jha P

Cureus29 Apr 2024Cited by 5 (Europe PMC)

PMID38817502PMCIDPMC11137324DOI10.7759/cureus.59319PepBankPUB-38817502

Summary

Semaglutide (Ozempic), a GLP-1 receptor agonist effective in weight management, and ziprasidone (Geodon), an antipsychotic with a lower risk of metabolic side effects, are well-established in treating type 2 diabetes and schizophrenia, respectively. However, their interactions and effects on psychiatric symptoms are less understood. In this study, we report a case of a 43-year-old male with schizophrenia and diabetes with exacerbated paranoid delusions upon semaglutide administration for weight loss; symptoms peaked at higher doses and subsided after dose reduction. Concurrently, serum ziprasidone levels were significantly elevated at the dose reduction, suggesting a pharmacokinetic interaction likely due to semaglutide-induced slowed gastric emptying affecting ziprasidone's absorption and metabolism. This study illustrates the need for careful monitoring of psychiatric symptoms and drug levels when these medications are used together. Additionally, further research into their interactions to optimize treatment for patients with coexisting metabolic and psychiatric conditions is warranted.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

1 result from studies that gave the peptide. 1 result from people.

01HumanCase report or seriesSafety outcome
In a 43-year-old man with schizophrenia and diabetes, paranoid delusions worsened on semaglutide, peaked at higher doses and subsided after dose reduction.
In plain wordsIn one man with schizophrenia and diabetes, paranoid delusions worsened while taking semaglutide and eased after the dose was lowered.
Peptide
Semaglutide
Outcome
IncreaseParanoid delusions on semaglutide
Study
n = 1
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
Dose not stated
Source sentences
Summary
exacerbated paranoid delusions upon semaglutide administration for weight loss; symptoms peaked at higher doses and subsided after dose reduction.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we report a case of a 43-year-old male with schizophrenia and diabetes with exacerbated paranoid delusions upon semaglutide administration for weight loss; symptoms peaked at higher doses and subsided after dose reduction.
Show in the study text Report a problemFND-3881750201

Studies that did not test the peptide alone1

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

02HumanNot a test of Semaglutide aloneCase report or seriesPharmacokinetics
In a man taking semaglutide and ziprasidone, serum ziprasidone levels were significantly elevated at the semaglutide dose reduction, suggesting a pharmacokinetic interaction.
In plain wordsIn one man taking semaglutide and ziprasidone, blood levels of ziprasidone were higher when the semaglutide dose was reduced, suggesting a drug interaction.
Peptide
Semaglutide
Outcome
IncreaseSerum ziprasidone level at semaglutide dose reduction
Study
n = 1
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Concurrently, serum ziprasidone levels were significantly elevated at the dose reduction, suggesting a pharmacokinetic interaction likely due to semaglutide-induced slowed gastric emptying affecting ziprasidone's absorption and metabolism.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we report a case of a 43-year-old male with schizophrenia and diabetes with exacerbated paranoid delusions upon semaglutide administration for weight loss; symptoms peaked at higher doses and subsided after dose reduction.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-3881750202

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.